Abnormalities of pulmonary function in patients with congestive heart failure, and reversal with ipratropium bromide☆
References (25)
- et al.
Abnormal pulmonary function specifically related to congestive heart failure: comparison of patients before and after cardiac transplantation
Am J Med
(1990) - et al.
The effect of ipratropium bromide on maximal exercise capacity in asthmatic and non-asthmatic men
Respir Med
(1992) - et al.
Exercise ventilation and pulmonary artery wedge pressure in chronic stable heart failure
Am J Cardiol
(1986) An Account of the Foxglove, and Some of Its Medical Uses: With Practical Remarks on Dropsy and Other Diseases
(1785)- et al.
Cardiac asthma (paroxysmal cardiac asthma) and the syndrome of left ventricular failure
JAMA
(1933) - et al.
Pulmonary function abnormalities in chronic severe cardiomyopathy preceding cardiac transplantation
Am Rev Respir Dis
(1992) - et al.
Bronchial hyperresponsiveness in heart failure. Letter
N Engl J Med
(1993) - et al.
Bronchial hyperreactivity in chronic left ventricular failure (abstr)
J Am Coll Cardiol
(1991) Bronchial hyperresponsiveness to methacholine in patients with impaired left ventricular function (letter)
N Engl J Med
(1989)- et al.
Pulmonary abnormalities in congestive heart failure: reversal by the inhaled anticholinergic agent ipratropium bromide (abstr)
J Am Coll Cardiol
(1992)
Bronchodilator action of inhaled fenoterol and ipratropium in normal subjects: a teaching exercise for medical students
Br J Clin Pharmacol
Dyspnea: physiological and pathophysiological mechanisms
Annual Reviews of Medicine
Cited by (42)
Japanese guidelines for adult asthma 2020
2020, Allergology InternationalCitation Excerpt :Non-selective β-blockers are not safe for use even in those patients with adequately controlled asthma.129 Anticholinergics can be used to improve dyspnea and respiratory function in patients with heart failure.130 Aminophylline and controlled-release theophylline preparations have been approved for insurance reimbursement for the treatment of cardiac asthma and congestive heart failure, and they are effective at suppressing myocardial stress and reducing pulmonary edema.131
Pulmonary function impairment in patients with chronic heart failure: Lower limit of normal versus conventional cutoff values
2014, Heart and Lung: Journal of Acute and Critical CareBronchodilator responsiveness in patients with chronic heart failure
2013, Heart and Lung: Journal of Acute and Critical CareCitation Excerpt :There are, however, only few studies concerning the beneficial effects of bronchodilators in patients with HF. Improvements in pulmonary function,4–10 dyspnea,10 and exercise performance7 have been reported. Some investigators have even observed an increase of mean forced expiratory volume in 1 s (FEV1) greater than 200 mL and 12% in patients with HF,6,8,9 especially in those with AO,8 left ventricular systolic dysfunction (LVSD),9 and during acute decompensation of HF.6
Assessment of respiratory mechanics by impulse oscillometry in orthopneic patients with acute left ventricular failure
2011, Heart and Lung: Journal of Acute and Critical CareExpiratory flow limitation is associated with orthopnea and reversed by vasodilators and diuretics in left heart failure
2005, ChestCitation Excerpt :It is important to recognize that we investigated patients with acutely increasing (ie, over days) exertional dyspnea and the presence of dyspnea at rest due to moderate-to-severe pulmonary congestion, but without obvious signs of “cardiac” asthma or acute pulmonary edema. In patients experiencing chronic CHF, besides the presence of a restrictive ventilatory defect due to enlarged heart size, increased intrathoracic fluids,1 and impaired inspiratory muscle strength,17 the occurrence of airway narrowing caused by different mechanisms has been demonstrated,2,18–20 mainly during episodes of acute decompensation21,22 and on adopting the supine posture.8,23 The consequent rise in elastic and resistive loads imposed on the inspiratory muscles when lying down has been related to increased breathlessness in recumbent CHF patients.7,8
- ☆
This study was supported in part by Grant 1K11 HL02361 from the National Institutes of Health, Bethesda, Maryland, to Dr. Kindman and by a grant from the Boehringer Ingelheim Pharmaceutical Corporation, Ridgefield, Connecticut.